

# Fully Underwritten Renounceable Entitlement Offer and Unmarketable Parcel Sale Facility

## Key Points

- **Fully underwritten pro-rata renounceable entitlement offer to raise ~\$913k**
- **Eligible shareholders may apply for three New Shares for every eight shares held on the Record Date, together with one free attaching Entitlement Option for every three New Shares issued**
- **Offer Price for New Shares is \$0.01 per share, representing a discount of 9.1% to the closing price on ASX on 7 October 2026**
- **Entitlement Options will have an exercise price of \$0.02, expiring two years and six months after the date of issue**
- **Cynata also intends to establish Unmarketable Parcel Sale Facility, to allow shareholdings with a market value of less than \$500 to be sold without paying brokerage fees**

Melbourne, Australia; 8 October 2026: [Cynata Therapeutics Limited](#) (ASX: "CYP", "Cynata", or the "Company"), advises that it is undertaking a three-for-eight fully underwritten pro-rata renounceable entitlement offer to raise approximately \$913,000 (before costs) ("**Entitlement Offer**").

The Company's core asset is currently the Cymerus™ platform, which offers a genuinely differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. The Board is now focused on evaluating the future development pathways available for this technology, and the broader strategic options open to the Company. This includes seeking opportunities to realise value from the Cymerus™ technology and obtain rights to new assets.

The funds raised from the Entitlement Offer will be used to pay for professional adviser, Director and consultant fees in connection with the Company's strategic objectives, pay the costs of the Entitlement Offer, and provide working capital.

## Entitlement Offer

Eligible Shareholders may apply for three new, fully paid ordinary shares ("**New Shares**") for every eight shares held on the Record Date, together with one free attaching Entitlement Option for every three New Shares issued. The Offer Price for the New Shares is \$0.01 per New Share, representing a discount of 9.1% to both the closing price and the five-day volume-weighted average price as at market-close on 7 October 2026.

Eligible Shareholders are those Cynata shareholders who:

- are a registered holder of CYP shares at 7.00pm (Melbourne time) on the Entitlement Offer Record Date, being Tuesday, 13 October 2026;
- have a registered address in either Australia, New Zealand or Singapore; and
- are not in the United States and not acting for the account or benefit of a person in the United States.

Given the Entitlement Offer is renounceable, Eligible Shareholders may also trade their Entitlements on ASX during the Entitlement trading period.

The Company is offering Options to participants in the Entitlement Offer for nil cash consideration on the basis of one option for every three New Shares issued under the Entitlement Offer (“**Entitlement Options**”). Each Entitlement Option will have an exercise price of \$0.02 and will be exercisable on or before the date that is two years and six months after the date of issue of the Entitlement Options.

The Entitlement Options will not be quoted on ASX.

The Entitlement Offer is lead managed and fully underwritten by Caravel Securities Pty Ltd ACN 665 357 915 (“the **Underwriter**”). In consideration for services to be performed by the Underwriter in connection with the Entitlement Offer (and in addition to its cash fees described in the Appendix 3B to be lodged by the Company in connection with the Entitlement Offer), the Company has agreed to offer the Underwriter (or nominee(s)) 18,000,000 options to be issued on completion of the Entitlement Offer (“**Underwriter Options**”). The Underwriter Options are being offered to the Underwriter (or nominee(s)) on the same terms as the Entitlement Options and will be issued utilising the Company’s available capacity under Listing Rule 7.1.

#### Indicative Timetable

| Event                                                                                                                                          | Date (2026)           |
|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Prospectus lodged with ASIC and ASX and Appendix 3B lodged with ASX                                                                            | Thursday, 8 October   |
| Ex-date for Entitlement Offer<br>Entitlement trading commences on a deferred settlement basis                                                  | Monday, 12 October    |
| <b>Record Date</b> for eligibility to participate in the Entitlement Offer                                                                     | Tuesday, 13 October   |
| <b>Offer Opening Date</b><br>Prospectus and Entitlement & Acceptance Form available to Eligible Shareholders<br>Underwriter Option Offer opens | Friday, 16 October    |
| <b>Entitlement trading</b> ends at ASX market close                                                                                            | Tuesday, 20 October   |
| <b>Offer Closing Date</b><br>Entitlement Offer and Underwriter Option Offer close                                                              | Tuesday, 27 October   |
| Announcement of results of the Entitlement Offer                                                                                               | Friday, 30 October    |
| Issue of New Shares and Entitlement Options under the Entitlement Offer and Underwriter Options under Underwriter Option Offer                 | Tuesday, 3 November   |
| Trading of New Shares issued under the Entitlement Offer                                                                                       | Wednesday, 4 November |
| Despatch of holding statements for New Shares and Options                                                                                      | Wednesday, 4 November |

Cynata reserves the right to vary these times and dates, by agreement with the Underwriter. All times are Melbourne times.

## Prospectus

A Prospectus containing information in respect of the Entitlement Offer and Entitlement Options, together with information regarding the Company and a description of the key risks involved in an investment in the Company, has been lodged with ASIC and ASX today, 8 October 2026.

A personalised Entitlement and Acceptance Form, accompanied by the Prospectus, will be made available to Eligible Shareholders on Friday, 16 October 2026 on the [Automic portal](#).<sup>1</sup> Eligible Shareholders should read the Prospectus in full before deciding whether to subscribe for New Shares and Entitlement Options.

Eligible Shareholders will need to provide their Securityholder Reference Number (SRN) or Holder Identification Number (HIN) and postcode to participate in the Entitlement Offer.

Eligible Shareholders will also be able to access a copy of the Prospectus on ASX's website ([www.asx.com.au](http://www.asx.com.au)) and Cynata's website.

A Target Market Determination will also be available on the Company's website.

## Unmarketable Parcel Sale Facility

The Company also intends to establish an Unmarketable Parcel Sale Facility, under which parcels of fully paid ordinary shares in CYP with a market value of less than A\$500 on the relevant record date may be sold without brokerage fees.

Further details of the Unmarketable Parcel Sale Facility will be announced separately.

**ENDS-**

**Authorised for release by the Board of Directors**

**CONTACT:** [investors@cynata.com](mailto:investors@cynata.com)

## About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited's (ASX: CYP) core asset is currently the Cymerus™ platform, which offers a genuinely differentiated approach to manufacturing mesenchymal stromal cells at commercial scale from a single, consistent cell source. The Board is now focused on evaluating the future development pathways available for this technology, and the broader strategic options open to the Company. This includes seeking opportunities to realise value from the Cymerus™ technology and obtaining rights to new assets.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Pty Ltd](#).

<sup>1</sup> <https://portal.automic.com.au/investor/home>